Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1239-1248

  Heutte, Natacha ^a   Haioun, Corinne ^b   Feugier, Pierre ^c   Coiffier, Bertrand ^d   Tilly, Herve ^e   Ferme, Christophe ^f   Gabarre, Jean ^g   Morschhauser, Franck ^h   Gisselbrecht, Christian ⁱ   Mounier, Nicolas ^j  

^a UNIVERSITÉ DE CAEN   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e CENTRE HENRI BECQUEREL   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

more..

Author keywords

autotransplant; Lymphoma; quality of life; rituximab maintenance

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ANOREXIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; CONVALESCENCE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HUMAN; INJECTION; INSOMNIA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK REDUCTION; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MODELS, STATISTICAL; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 79959613069     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.566951     Document Type: Article

References (27)

1. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. (Pubitemid 46348180)
2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511. (Pubitemid 30082188)
4. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
5. Arranz R, Conde E, Grande C, et al. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Eur J Haematol 2008;80:227-235. (Pubitemid 351253465)
6. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation comparedwith MACOP-B in aggressive B-cell lymphoma. N Engl JMed 1997;336:1290-1297. (Pubitemid 27187782)
7. Glass B, Kloess M, Bentz M, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006;107:3058-3064.
8. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev 2007;33:338-346. (Pubitemid 46778207)
9. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol- a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-3030. (Pubitemid 30644128)
10. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350: 1287-1295. (Pubitemid 38375363)
11. Stewart DA, Bahlis N, Valentine K, et al. Upfront double highdose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006;107:4623-4627. (Pubitemid 43882606)
12. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242. (Pubitemid 34438862)
13. Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127. (Pubitemid 46638950)
14. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
15. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large- B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
16. Haioun C, Mounier N, Emile JF, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol 2009;20:1985-1992.
17. Fagnoni P, Milpied N, Limat S, et al. Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma. Pharmacoeconomics 2009;27:55-68.
18. Mounier N, Haioun C, Cole BF, et al. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). Blood 2000;95:3687-3692. (Pubitemid 30412838)
19. Andrykowski MA, Bishop MM, Hahn EA, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol 2005;23:599-608. (Pubitemid 46224238)
20. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 2009; 114:7-19.
21. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376. (Pubitemid 23073154)
22. Fayers P, Aaronson N, Bjordal K, et al. EORTC QLQ-C30 scoring manual. 2nd ed. Brussels: EORTC Quality of Life Study Group; 1999.
23. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144. (Pubitemid 28041591)
24. Ganz PA, Moinpour CM, Pauler DK, et al. Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 2003;21:3512-3519. (Pubitemid 46594085)
25. Lee SJ, Joffe S, Kim HT, et al. Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood 2004;104:2194-2200. (Pubitemid 39297879)
26. Witzens-HarigM, Reiz M, Heiss C, et al. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial. Ann Hematol 2009;88:51-57.
27. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777-783. (Pubitemid 38129532)